PAR •
Healthcare •
Biotechnology •
Quote as of 09/18/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization151.58 mln
Float55.16 mln
Earnings Date11/06/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.47
Reliable
Relative Strength
0
/ 100
Severely lagging
Debt / Equity
2.06
Very high leverage
Pre-Tax Margin
-117%
Severely loss-making
ROE
-87.36
Deeply negative
Business Description
Founded in 1999 and based in Paris, France, Cellectis is a clinical-stage company working to treat cancer and other serious diseases by engineering modified immune cells. Its approach centers on altering the genetic makeup of T-cells so they can be prepared in advance and used across multiple patients, rather than being tailored individually. The company currently has several treatment programs in active clinical testing, targeting blood cancers such as leukemia, B-cell lymphoma, and large B-cell lymphoma, as well as kidney cancer and melanoma.
